Open Label Extension Study of Conatumumab and AMG 479

- The folks at Amgen are studying the effects of FOLFOX6; Conatumumab; Ganitumab; Bevacizumab on Metastatic Cancer, Lymphoma, Locally Advanced, Colorectal Cancer, Carcinoid, Advanced Solid Tumors, Non-Small Cell Lung Cancer, Sarcoma and Solid Tumors in individuals ages 18 years and older. This clinical trial is slated to start March 2011 and is expected to end circa December 2014.

866-572-6436
Overall Study Contact Info
StatusName Contact Phone
RecruitingAmgen Call Center866-572-6436

This study is officially titled, "A Phase 2 Open Label Extension Study of Conatumumab and AMG 479."

Locations

Research Site

Barcelona, Catalu¤a - Recruiting

Research Site

Szczecin, Poland - Recruiting

Research Site

Ogden, Utah - Recruiting

Research Site

Houston, Texas - Recruiting

Research Site

Memphis, Tennessee - Recruiting

Research Site

Buffalo, New York - Recruiting

Research Site

Tampa, Florida - Recruiting

Research Site

Denver, Colorado - Completed

Research Site

Duarte, California - Completed

Research Site

La Jolla, California - Completed

For more study details, please visit this link to ClinicalTrials.gov record, which is the source of this webpage.